Such challenges can appear in one or several sensory systems of the somatosensory system, vestibular system, proprioceptive system, interoceptive system, auditory system, visual system, olfactory system, and gustatory system.While many people can present one or two symptoms, sensory processing disorder has to have a clear functional impact on the persons life:
Signs of over-responsivity, including, for example, dislike of textures such as those found in fabrics, foods, grooming products or other materials found in daily living, to which most people would not react, and serious discomfort, sickness or threat induced by normal sounds, lights, ambient temperature, movements, smells, tastes, or even inner sensations such as heartbeat.Signs of under-responsivity, including sluggishness and lack of responsiveness. Sensory cravings, including, for example, fidgeting, impulsiveness, and/or seeking or making loud, disturbing noises; and sensorimotor-based problems, including slow and uncoordinated movements or poor handwriting. Sensory discrimination problems, which might manifest themselves in behaviors such as things constantly dropped.Symptoms may vary according to the disorders type and subtype present. Relationship to other disorders
Sensory integration and processing difficulties can be a feature of a number of disorders, including anxiety problems, attention deficit hyperactivity disorder (ADHD), food intolerances, behavioral disorders, and particularly, autism spectrum disorders.
Elapegademase, sold under the brand name Revcovi, is a medication for the treatment of the rare disease adenosine deaminase deficiency-SCID in children and adults.It is a recombinant enzyme that is administered weekly by intramuscular injection.Elapegademase may interact with PEGylated drugs.Elapegademase-lvlr was approved by the U.S. Food and Drug Administration (FDA) in 2018. Leadiant Biosciences was awarded a priority review voucher for its development under the pediatric rare diseases program. References
External links
"Elapegademase". Drug Information Portal. U.S. National Library of Medicine.